Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;5(4):448-51.
doi: 10.3980/j.issn.2222-3959.2012.04.08. Epub 2012 Aug 18.

Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model

Ayhan Dursun  1 , Mustafa Kemal Arici, Feyza Dursun, Ayse Vural Ozec, Mustafa Ilker Toker, Haydar Erdogan, Aysen Topalkara
Affiliations

Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model

Ayhan Dursun et al. Int J Ophthalmol. 2012.

Abstract

Aim: To investigate the effects of bevacizumab and ranibizumab on corneal neovascularization in an alkali burn-induced model of corneal angiogenesis.

Methods: Fifteen Wistar albino rats were divided randomly into 3 groups after chemical cauterization of the cornea. The first group received a single dose of 0.1mL saline solution as a control group whereas second and third groups received a single dose of 2.5mg bevacizumab or 1mg ranibizumab by subconjunctival injection, respectively. After three weeks, the rat corneas were evaluated by biomicroscopy and corneal photographs were taken. The percentage of neovascularization area, length of the longest new vessel, corneal edema and corneal opacity scores were assessed.

Results: The analysis of digital photographs showed that the percentage of neovascularization area to the total corneal area, the length of the longest new vessel, corneal edema and opacity scores were significantly lower in both study groups compared to the control group (P<0.05). Additionally, the percentage of corneal neovascularization area, the length of the longest new vessel and corneal opacity score were less with bevacizumab than ranibizumab.

Conclusion: Subconjunctival bevacizumab and ranibizumab treatments may be effective methods in reducing corneal neovascularization. Furthermore, bevacizumab is more effective than ranibizumab in the inhibition of corneal neovascularization.

Keywords: bevacizumab; corneal neovascularisation; ranibizumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1. View of rat cornea
A: Before chemical caterization; B: Bevacizumab group; C: Ranibizumab group; D: Control group.
Figure 2
Figure 2. Percentage of neovascularization areas in control, bevacizumab (2.5mg) and ranibizumab (1mg) groups
aP<0.05 vs control group; cP<0.05 vs both control and ranibizumab groups.
Figure 3
Figure 3. The longest new vessel lengths in corneas in control, bevacizumab (2.5mg) and ranibizumab (1mg) groups
aP<0.05 vs control group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12(4):242–249. - PubMed
    1. Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, Laibson PR, Cohen EJ. Corneal neovascularization after penetrating keratoplasty. Cornea. 1995;14(6):604–609. - PubMed
    1. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41(9):2514–2522. - PubMed
    1. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin) Br J Ophthalmol. 2007;91(6):804–807. - PMC - PubMed
    1. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48(6):2545–2552. - PubMed

LinkOut - more resources